|
1
|
Pan ST, Zhou ZW, He ZX, Zhang X, Yang T,
Yang YX, Wang D, Qiu JX and Zhou SF: Proteomic response to
5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human
non-small cell lung cancer A549 cells determined by the
stable-isotope labeling by amino acids in cell culture (SILAC)
approach. Drug Des Devel Ther. 9:937–968. 2015.PubMed/NCBI
|
|
2
|
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang
WJ, Wu F, Fei Y, Wang L and Liang ZQ: Cathepsin L
upregulation-induced EMT phenotype is associated with the
acquisition of cisplatin or paclitaxel resistance in A549 cells.
Acta Pharmacol Sin. 37:1606–1622. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kallianos A, Tsimpoukis S, Zarogoulidis P,
Darwiche K, Charpidou A, Tsioulis I, Trakada G, Porpodis K,
Spyratos D, Panoutsopoulos A, et al: Measurement of exhaled
alveolar nitrogen oxide in patients with lung cancer: A friend from
the past still precious today. Onco Targets Ther. 6:609–613.
2013.PubMed/NCBI
|
|
4
|
Jiang M, Zhong T, Zhang W, Xiao Z, Hu G,
Zhou H and Kuang H: Reduced expression of miR-205-5p promotes
apoptosis and inhibits proliferation and invasion in lung cancer
A549 cells by upregulation of ZEB2 and downregulation of erbB3. Mol
Med Rep. 15:3231–3238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yuan Y, Zheng S, Li Q, Xiang X, Gao T, Ran
P, Sun L, Huang Q, Xie F, Du J and Xiao C: Overexpression of
miR-30a in lung adenocarcinoma A549 cell line inhibits migration
and invasion via targeting EYA2. Acta Biochim Biophys Sin
(Shanghai). 48:220–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keith RL and Miller YE: Lung cancer
chemoprevention: Current status and future prospects. Nat Rev Clin
Oncol. 10:334–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Godugu C, Patel AR, Doddapaneni R,
Marepally S, Jackson T and Singh M: Inhalation delivery of
Telmisartan enhances intratumoral distribution of nanoparticles in
lung cancer models. J Control Release. 172:86–95. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsuyama M, Funao K, Kuratsukuri K,
Tanaka T, Kawahito Y, Sano H, Chargui J, Touraine JL, Yoshimura N
and Yoshimura R: Telmisartan inhibits human urological cancer cell
growth through early apoptosis. Exp Ther Med. 1:301–306. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li P, Koike T, Jiang HY, Wang ZH, Kawata Y
and Oshida Y: Acute treatment with candesartan cilexetil, an
angiotensin II type 1 receptor blocker, improves insulin
sensitivity in high-fructose-diet-fed rats. Horm Metab Res.
44:286–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marquardt G, Schulz TF and Schweighofer B:
Angiogenesis in cancer. Nature. 407:249–257. 2012.
|
|
11
|
Celus W, Di Conza G, Oliveira AI, Ehling
M, Costa BM, Wenes M and Mazzone M: Loss of caveolin-1 in
metastasis-associated macrophages drives lung metastatic growth
through increased angiogenesis. Cell Rep. 21:2842–2854. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Imai N, Hashimoto T, Kihara M, Yoshida S,
Kawana I, Yazawa T, Kitamura H and Umemura S: Roles for host and
tumor angiotensin II type 1 receptor in tumor growth and
tumor-associated angiogenesis. Lab Invest. 87:189–198. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hinsley EE, de Oliveira CE, Hunt S,
Coletta RD and Lambert DW: Angiotensin 1–7 inhibits angiotensin
II-stimulated head and neck cancer progression. Eur J Oral Sci.
125:247–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chan SMH, Lau YS, Miller AA, Ku JM,
Potocnik S, Ye JM, Woodman OL and Herbert TP: Angiotensin II causes
β-cell dysfunction through an ER stress-induced proinflammatory
response. Endocrinology. 158:3162–3173. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Araújo Júnior RF, Leitão Oliveira AL,
de Melo Silveira RF, de Oliveira Rocha HA, de França Cavalcanti P
and de Araújo AA: Telmisartan induces apoptosis and regulates Bcl-2
in human renal cancer cells. Exp Biol Med (Maywood). 240:34–44.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sukumaran S, Patel HJ and Patel BM:
Evaluation of role of telmisartan in combination with
5-fluorouracil in gastric cancer cachexia. Life Sci. 154:15–23.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee LD, Mafura B, Lauscher JC, Seeliger H,
Kreis ME and Gröne J: Antiproliferative and apoptotic effects of
telmisartan in human colon cancer cells. Oncol Lett. 8:2681–2686.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan is
a potent target for prevention and treatment in human prostate
cancer. Oncol Rep. 20:295–300. 2008.PubMed/NCBI
|
|
19
|
Funao K, Matsuyama M, Kawahito Y, Sano H,
Chargui J, Touraine JL, Nakatani T and Yoshimura R: Telmisartan as
a peroxisome proliferator-activated receptor-γ ligand is a new
target in the treatment of human renal cell carcinoma. Mol Med Rep.
2:193–198. 2009.PubMed/NCBI
|
|
20
|
Li J, Chen L, Yu P, Liu B, Zhu J and Yang
Y: Telmisartan exerts anti-tumor effects by activating peroxisome
proliferator-activated receptor-γ in human lung adenocarcinoma A549
cells. Molecules. 19:2862–2876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu TT, Niu HS, Chen LJ, Cheng JT and Tong
YC: Increase of human prostate cancer cell (DU145) apoptosis by
telmisartan through PPAR-delta pathway. Eur J Pharmacol. 775:35–42.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cambados N, Walther T, Nahmod K, Tocci JM,
Rubinstein N, Böhme I, Simian M, Sampayo R, Del Valle Suberbordes
M, Kordon EC and Schere-Levy C: Angiotensin-(1–7) counteracts the
transforming effects triggered by angiotensin II in breast cancer
cells. Oncotarget. 8:88475–88487. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sobczuk P, Szczylik C, Porta C and
Czarnecka AM: Renin angiotensin system deregulation as renal cancer
risk factor. Oncol Lett. 14:5059–5068. 2017.PubMed/NCBI
|
|
24
|
Penafuerte CA, Gagnon B, Sirois J, Murphy
J, MacDonald N and Tremblay ML: Identification of
neutrophil-derived proteases and angiotensin II as biomarkers of
cancer cachexia. Br J Cancer. 114:680–687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rodrigues-Ferreira S, Abdelkarim M,
Dillenburg-Pilla P, Luissint AC, di-Tommaso A, Deshayes F, Pontes
CL, Molina A, Cagnard N and Letourneur F: Angiotensin II
facilitates breast cancer cell migration and metastasis. PLos One.
7:e356672012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masamune A, Hamada S, Kikuta K, Takikawa
T, Miura S, Nakano E and Shimosegawa T: The angiotensin II type I
receptor blocker olmesartan inhibits the growth of pancreatic
cancer by targeting stellate cell activities in mice. Scand J
Gastroenterol. 48:602–609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kinoshita J, Fushida S, Harada S, Yagi Y,
Fujita H, Kinami S, Ninomiya I, Fujimura T, Kayahara M, Yashiro M,
et al: Local angiotensin II-generation in human gastric cancer:
Correlation with tumor progression through the activation of
ERK1/2, NF-kappaB and survivin. Int J Oncol. 34:1573–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arafat HA, Gong Q, Chipitsyna G, Rizvi A,
Saa CT and Yeo CJ: Antihypertensives as novel antineoplastics:
Angiotensin-I-converting enzyme inhibitors and angiotensin II type
1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll
Surg. 204:996–1005. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
George AJ, Thomas WG and Hannan RD: The
renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev
Cancer. 10:745–759. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liles C, Li H, Veitla V, Liles JT, Murphy
TA, Cunningham MW, Yu X and Kem DC: AT2R autoantibodies block
angiotensin II and AT1R autoantibody-induced vasoconstriction.
Hypertension. 66:830–835. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kosugi M, Miyajima A, Kikuchi E, Kosaka T,
Horiguchi Y and Murai M: Effect of angiotensin II type 1 receptor
antagonist on tumor growth and angiogenesis in a xenograft model of
human bladder cancer. Hum Cell. 20:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Liu J, Chen J, Li X, Wu Y, Chen
H, Wu W, Zhang K and Gu L: Angiotensin receptor blockers (ARBs)
reduce the risk of lung cancer: A systematic review and
meta-analysis. Int J Clin Exp Med. 8:12656–12660. 2015.PubMed/NCBI
|
|
33
|
Kakuta H, Sudoh K, Sasamata M and
Yamagishi S: Telmisartan has the strongest binding affinity to
angiotensin II type 1 receptor: Comparison with other angiotensin
II type 1 receptor blockers. Int J Clin Pharmacol Res. 25:41–46.
2005.PubMed/NCBI
|
|
34
|
Wei JC, Zhang T and Yang P: Effect of
gambogic acid on cell apoptosis and expressions of Bax, Bcl-2 and
Caspase-3 in colorectal cancer cells with. J Pract Med. 2016.
|
|
35
|
Mao YQ, Li XR and Lei S: Effect of several
anti-tumor drugs on apoptosis induction in jurkat cell line.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 14:681–685. 2006.(In Chinese).
PubMed/NCBI
|
|
36
|
González-Pérez PP and Cárdenas-García M:
Modeling and simulation of molecular mechanism of action of dietary
polyphenols on the inhibition of anti-apoptotic PI3K/AKT pathway.
Comput Mol Biosci. 3:39–52. 2013. View Article : Google Scholar
|
|
37
|
Guo H, Cui H, Peng X, Fang J, Zuo Z and
Deng J, Wang X, Wu B, Chen K and Deng J: Modulation of the PI3K/Akt
pathway and Bcl-2 family proteins involved in chicken's tubular
apoptosis induced by nickel chloride (NiCl2). Int J Mol
Sci. 16:22989–23011. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Phatak NR, Stankowska DL and
Krishnamoorthy RR: Bcl-2, Bcl-xL and p-AKT are involved in
neuroprotective effects of transcription factor Brn3b in an ocular
hypertension rat model of glaucoma. Mol Vis. 22:1048–1061.
2016.PubMed/NCBI
|
|
39
|
Song T, Wang L, Mo Z, Mao L, Ma X, Niu R,
Gu K, Yan R, Ma P, Qi Y and Jiao Q: Expression of p-Akt in ovarian
serous carcinoma and its association with proliferation and
apoptosis. Oncol Lett. 7:59–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Premkumar DR, Jane EP, DiDomenico JD,
Vukmer NA, Agostino NR and Pollack IF: ABT-737 synergizes with
bortezomib to induce apoptosis, mediated by bid cleavage, bax
activation, and mitochondrial dysfunction in an Akt-dependent
context in malignant human glioma cell lines. J Pharmacol Exp Ther.
341:859–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bratton MR, Duong BN, Elliott S, Weldon
CB, Beckman BS, McLachlan JA and Burow ME: Regulation of
ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk:
Implications for breast cancer cell survival. Int J Oncol.
37:541–550. 2010.PubMed/NCBI
|
|
42
|
Hamunyela RH, Serafin AM and Akudugu JM:
Strong synergism between small molecule inhibitors of HER2, PI3K,
mTOR and Bcl-2 in human breast cancer cells. Toxicol In Vitro.
38:117–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Halacli SO and Dogan AL: FOXP1 regulation
via the PI3K/AKT/p70S6K signaling pathway in breast cancer cells.
Oncol Lett. 9:1482–1488. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu W, Ren H, Ren J, Yin T, Hu B, Xie S,
Dai Y, Wu W, Xiao Z, Yang X and Xie D: The role of
EGFR/PI3K/AKT/cyclinD1 signaling pathway in acquired middle ear
cholesteatoma. Mediators Inflamm. 2013:6512072013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao S, Yi M, Yuan Y, Zhuang W, Zhang D,
Yu X, Chen X, Teng B, Guan Z and Zhang Y: Expression of AKAP95,
Cx43, CyclinE1 and CyclinD1 in esophageal cancer and their
association with the clinical and pathological parameters. Int J
Clin Exp Med. 8:7324–7332. 2015.PubMed/NCBI
|
|
46
|
Cheng R, Liu YJ, Cui JW, Yang M, Liu XL,
Li P, Wang Z, Zhu LZ, Lu SY, Zou L, et al: Aspirin regulation of
c-myc and cyclinD1 proteins to overcome tamoxifen resistance in
estrogen receptor-positive breast cancer cells. Oncotarget.
8:30252–30264. 2017.PubMed/NCBI
|
